X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (23) 23
humans (22) 22
male (20) 20
female (16) 16
adult (15) 15
aged (13) 13
middle aged (12) 12
hematology (9) 9
aged, 80 and over (7) 7
treatment outcome (7) 7
oncology (6) 6
adolescent (5) 5
analysis (5) 5
animals (5) 5
antineoplastic agents - therapeutic use (5) 5
chronic myeloid leukemia (5) 5
protein kinase inhibitors - therapeutic use (5) 5
therapy (5) 5
young adult (5) 5
antineoplastic agents - administration & dosage (4) 4
cancer (4) 4
chemotherapy (4) 4
clinical trials (4) 4
fusion proteins, bcr-abl - genetics (4) 4
japan (4) 4
leukemia (4) 4
lymphomas (4) 4
stem cells (4) 4
time factors (4) 4
transplantation (4) 4
antifungal agents - therapeutic use (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
biochemistry & molecular biology (3) 3
chronic myelogenous leukemia (3) 3
dasatinib (3) 3
follow-up (3) 3
glycosaminoglycans (3) 3
hematopoietic stem cell transplantation (3) 3
hematopoietic stem cells (3) 3
leukemia, myeloid, acute - drug therapy (3) 3
leukemia, myeloid, acute - pathology (3) 3
leukemia, myeloid, chronic-phase - drug therapy (3) 3
leukemia, myeloid, chronic-phase - genetics (3) 3
medicine & public health (3) 3
medicine, research & experimental (3) 3
progression-free survival (3) 3
protein kinase inhibitors - adverse effects (3) 3
retrospective studies (3) 3
transplantation, homologous (3) 3
allogenic stem cell transplantation (2) 2
amphotericin b - administration & dosage (2) 2
amphotericin b - therapeutic use (2) 2
anemia, aplastic - therapy (2) 2
antifungal agents - administration & dosage (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
care and treatment (2) 2
case report (2) 2
chromatography (2) 2
cyclophosphamide (2) 2
cytogenetic responses (2) 2
dasatinib - adverse effects (2) 2
dasatinib - therapeutic use (2) 2
diagnosis, differential (2) 2
doxorubicin (2) 2
febrile neutropenia (2) 2
gallium (2) 2
graft vs host disease - pathology (2) 2
granulocyte colony stimulating factor (2) 2
hematologic diseases - therapy (2) 2
hematological malignancies (2) 2
hematopoietic stem cell transplantation - methods (2) 2
hla antigens - immunology (2) 2
hyaluronic acid - metabolism (2) 2
imatinib mesylate - administration & dosage (2) 2
immunocompromised host (2) 2
immunocompromised human hosts (2) 2
interferon (2) 2
kinetics (2) 2
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (2) 2
leukemia, myeloid, acute - mortality (2) 2
leukemia, myeloid, chronic-phase - diagnosis (2) 2
leukocytes, mononuclear - metabolism (2) 2
liposomal amphotericin b (2) 2
liver - enzymology (2) 2
lung diseases, fungal - diagnosis (2) 2
lung diseases, fungal - drug therapy (2) 2
lung diseases, fungal - microbiology (2) 2
lymphoma (2) 2
medicine, general & internal (2) 2
metabolism (2) 2
minimal residual disease (2) 2
molecular response (2) 2
molecular weight (2) 2
multivariate analysis (2) 2
neutropenia (2) 2
nilotinib (2) 2
opportunistic infections - diagnosis (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
by Trotman, Judith and Barrington, Sally F and Belada, David and Meignan, Michel and MacEwan, Robert and Owen, Carolyn and Ptáčník, Václav and Rosta, András and Fingerle-Rowson, Günter R and Zhu, Jiawen and Zhu, Jun and Nielsen, Tina and Sahin, Deniz and Hiddemann, Wolfgang and Marcus, Robert E and Davies, Andrew and Hertzberg, Mark and Grigg, Andrew and Cannell, Paul and Quach, Hang and Opat, Stephen and Tam, Constantine and Marlton, Paula and Janssens, Ann and Offner, Fritz and Van eygen, Koen and Sangha, Randeep and Mckay, Pam and Wilson, Jonathan and Van Der Jagt, Richard and Roitman, Daryl and Trneny, Marek and Mayer, Jiri and Le Du, Katell and Solal-Celigny, Philippe and Cartron, Guillaume and Foussard, Charles and Frickhofen, Norbert and Schmidt, Peter and Graeven, Ullrich and Gaska, Tobias and Schlag, Rudolf and Sökler, Martin and Prange-Krex, Gabriele and Florschütz, Axel and Lindemann, Hans-Walter and Schimmelpfennig, Christoph and Tonndorf, Solveig and Hänel, Mathias and Hess, Georg and Schalk, Enrico and Hütten, Heiko and Doelken, Gottfried and Pfreundschuh, Michael and Keller, Ulrich and Herold, Michael and Forstpointner, Roswitha and Vehling-Kaiser, Ursula and Hoffmann, Martin and Borbenyi, Zita and Udvardy, Miklos and Demeter, Judit and Rambaldi, Alessandro and Morra, Enrica and Massimo, Federico and Majolino, Ignazio and Balzarotti, Monica and Semenzato, Gianpietro and Canales Albendea, Miguel Angel and Peñalver Parraga, Francisco Javier and Soler Campos, Alfonso and Sancho Cia, Juan Manuel and Marquez Navarro, Jose Antonio and Grande Garcia, Carlos and Nilsson-Ehle, Herman and Mccarthy, Helen and Pocock, Chris and Sadullah, Shalal and Malladi, Ram and Radford, John and Kanfer, Ed and Kruger, Anton and Culligan, Dominic and Dyer, Martin and Pettengell, Ruth and Seymour, John and Gribben, John and Al-Ismail, Saad and Al-Refaie, Faris and Blesing, Norbert and Macnamara, Christopher and O'callaghan, Ann and Haynes, Andrew and Follows, George and Johnson, Roderick and Cunningham, David and Bowles, Kristian and Collins, Graham and Gallop-Evans, Eve and Robinson, Stephen and ... and PET investigators GALLIUM study and PET investigators from the GALLIUM study
The Lancet Oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1530 - 1542
Journal Article
International Journal of Hematology, ISSN 0925-5710, 7/2012, Volume 96, Issue 1, pp. 84 - 93
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 2/2016, Volume 72, Issue 2, pp. 185 - 193
Dasatinib is a novel, oral, multi-targeted kinase inhibitor of breakpoint cluster region-abelson (BCR-ABL) and Src family kinases. The study investigated... 
Dasatinib | Pharmacodynamics | Biomedicine | Half maximal inhibitory concentration | Phamacokinetics | Pharmacology/Toxicology | Molecular response | CELLS | SAFETY | TYROSINE KINASE | NILOTINIB | PHILADELPHIA-CHROMOSOME | IMATINIB | DRUGS | BCR-ABL ACTIVITY | PHARMACOLOGY & PHARMACY | INHIBITOR | Leukocytes, Mononuclear - metabolism | Antigens, CD34 - metabolism | Oncogene Protein v-crk - antagonists & inhibitors | Humans | Middle Aged | Oncogene Protein v-crk - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Dasatinib - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Protein Kinase Inhibitors - pharmacokinetics | Leukocytes, Mononuclear - drug effects | Dasatinib - therapeutic use | Treatment Outcome | Dasatinib - pharmacology | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Aged | Dasatinib - adverse effects | Protein Kinase Inhibitors - pharmacology | Phosphotransferases | Analysis | Chronic myeloid leukemia | Pharmacology | Kinetics | Drug therapy | Leukemia | Chronic illnesses | Index Medicus
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2014, Volume 25, Issue suppl_5, pp. v61 - v61
Journal Article
European Journal of Haematology, ISSN 0902-4441, 01/2018, Volume 100, Issue 1, pp. 27 - 35
Journal Article
Leukemia Research, ISSN 0145-2126, 2016, Volume 51, pp. 11 - 18
Journal Article
British Journal of Haematology, ISSN 0007-1048, 08/2016, Volume 174, Issue 4, pp. 563 - 570
Pegfilgrastim is a pegylated form of the granulocyte‐colony stimulating factor, filgrastim. Herein, we report the results of a multicentre, randomized,... 
pegfilgrastim | (R) chemotherapy | febrile neutropenia | malignant lymphoma | CSF | CHASE | CHASE(R) chemotherapy | G-CSF | MORTALITY | MULTICENTER | ADULT CANCER-PATIENTS | COLONY-STIMULATING FACTOR | OPEN-LABEL | RECOMMENDATIONS | NON-HODGKINS-LYMPHOMA | UPDATE | HEMATOLOGY | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Rituximab - therapeutic use | Lymphoma - drug therapy | Adult | Female | Neutropenia - chemically induced | Rituximab - adverse effects | Etoposide - adverse effects | Double-Blind Method | Polyethylene Glycols | Etoposide - therapeutic use | Filgrastim - administration & dosage | Neutropenia - drug therapy | Recombinant Proteins - administration & dosage | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma - complications | Aged | Disease Management | Granulocyte Colony-Stimulating Factor - administration & dosage | Antimitotic agents | Chemotherapy | Granulocyte colony-stimulating factor | Clinical trials | Lymphomas | Antineoplastic agents | Cancer | Neutropenia | Index Medicus | G‐CSF | Haematological Malignancy | Research Paper
Journal Article